Y0001442
N-[(cis-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine
European Pharmacopoeia (EP) Reference Standard
Sinónimos:
N-[[cis-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Fórmula empírica (notación de Hill):
C19H27NO3
Número de CAS:
Peso molecular:
317.42
UNSPSC Code:
41116107
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
nateglinide
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
¿Está buscando productos similares? Visita Guía de comparación de productos
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
N-[(cis-4-Isopropylcyclohexyl)carbonyl]-ᴅ-phenylalanine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
related product
Referencia del producto
Descripción
Precios
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Certificados de análisis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Atención al cliente
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
F Zheng et al.
Journal of endocrinological investigation, 36(7), 489-496 (2013-01-18)
Recent studies highlight an important role of ghrelin in glucose homeostasis, while the association between ghrelin regulation and glucose fluctuation is unclear. We compared the effects of two postprandial hypoglycemic agents on ghrelin response and determined the contribution of ghrelin
Ranee Chatterjee et al.
American journal of hypertension, 26(6), 723-726 (2013-02-19)
Low and low-normal serum potassium is associated with an increased risk of diabetes. We hypothesized that the protective effect of valsartan on diabetes risk could be mediated by its effect of raising serum potassium. We analyzed data from the Nateglinide
Jatinder Kaur et al.
Journal of medicinal chemistry, 55(17), 7883-7891 (2012-08-25)
A new group of hybrid nitric oxide-releasing type II antidiabetic drugs possessing a 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (13 and 18), 1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (14 and 19), or nitrooxyethyl (15 and 20) moiety attached to the carboxylic acid group of the type II antidiabetic drugs nateglinide
Jian Luo et al.
Metabolism: clinical and experimental, 62(1), 90-99 (2012-09-18)
To develop a rapid, easy and clinically relevant in vivo model to evaluate novel insulin secretagogues on human islets, we investigated the effect of insulin secretagogues on functional human islets in a humanized mouse model. Human islets were transplanted under
Lauretta Maggi et al.
International journal of pharmaceutics, 454(1), 562-567 (2013-07-23)
Nateglinide is a non-sulphonylurea insulinotropic oral antidiabetic agent. The main problem in formulating an oral dosage form is its low solubility in aqueous media. This problem is particularly critical for an anti-diabetic drug because it should be administered just before
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico